The American peptide market is experiencing explosive growth, and cryptocurrency has become a key driver of this process. In the first quarter of 2026, sellers of these drugs received $32 million in digital assets from buyers — an impressive 700% year-over-year increase. On-chain analysis data confirms: Bitcoin is becoming the preferred means of payment in this gray market segment.

Peptides are marketed as products for weight loss, muscle gain, and life extension. Legal drugs undergo clinical trials and are sold in major pharmacy chains, but a significant portion of online trade operates in the shadows. Cheap analogs are shipped directly from foreign laboratories, often without a prescription or insurance, and the packaging may bear the label "not for human use."

Why cryptocurrency specifically?

Traditional banks and payment systems refuse to service such sellers due to high compliance risks. As a result, many suppliers accept payment exclusively in Bitcoin. Notably, for some buyers, this becomes their first experience with cryptocurrencies. For example, a 49-year-old marketer from the US named Zach, wanting to purchase retatrutide (an Eli Lilly drug), contacted a Chinese supplier. The supplier agreed to send 20 vials for $240 — three times cheaper than US retail — but required payment only in digital assets. Zach had to buy Bitcoin for the first time in his life.

Three waves of growth

Analysts identify three stages in the evolution of this market. Before 2025, it was a niche "underground" with a monthly inflow of about $200,000. Then the topic came to the attention of the Make America Healthy Again movement, coinciding with the appointment of Robert F. Kennedy Jr. as head of the US Department of Health and Human Services. No direct causal link is evident from on-chain data, but the coincidence is telling.

A sharp spike occurred in late 2025 when the peptide topic took over the TikTok subculture of looksmaxxing, obsessed with improving appearance. The average monthly inflow quadrupled to $9.9 million, and in peak months exceeded $10 million. The annual turnover of the peptide market was estimated to have reached $100 million as early as 2023, and in 2025, digital asset inflows into the sector amounted to $41.4 million — a 20% increase year-over-year. Experts compare this dynamic to the early stages of shadow online markets like Silk Road.

Major players are switching to stablecoins

The market is unevenly structured. The bulk of the volume comes from a narrow group of large sellers. Small players fluctuate between different coins, while large suppliers use almost exclusively Bitcoin and stablecoins. The latter are especially popular among sellers with an average deposit of $1,000 or more — this way they hedge against volatility in large and cross-border purchases.

The Chinese connection

The primary raw materials for peptides are produced in China. Local chemical companies are actively expanding their presence in this niche. Over the three quarters of last year, imports from China to the US doubled to over $300 million. Some suppliers entered the peptide business from the drug trade. For example, the Chinese company Bigreat Technology, which previously supplied precursors for fentanyl and amphetamines to Russia and Kazakhstan, created a separate legal entity — Zhengzhou DEPU Technology — to sell cosmetic peptides.

This case clearly demonstrates how cryptocurrency is penetrating new niches, servicing demand that the traditional financial system ignores. However, this also entails a serious risk: the lack of regulation and quality control of such drugs could lead to tragic consequences. The market is clearly following the path of the darknet, and regulators should pay the closest attention to this.